东亚药业(605177.SH)：上半年净亏损3022.83万元

Core Viewpoint - Dongya Pharmaceutical (605177.SH) reported a significant decline in both revenue and net profit for the first half of the year, indicating potential challenges in its operational performance [1] Financial Performance - The company achieved operating revenue of 415.8583 million yuan, a decrease of 35.85% compared to the same period last year [1] - The net profit attributable to shareholders of the listed company was -30.2283 million yuan, representing a decrease of 193.09% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -35.8809 million yuan, reflecting a decrease of 233.22% compared to the previous year [1]